胸腺肽α1治疗化疗所致神经系统副作用的初步研究

Primary Assessment of Treatment Effect of Thymosin-induced Neurotoxicity

背景与目的:临床研究发现胸腺肽α1(日达仙)可不同程度地减轻化疗引起的某些毒性反应(恶心、呕吐、乏力),但胸腺肽α1能否改善化疗所致的神经系统毒性作用尚未见报道。本研究拟观察胸腺肽α1对神经系统的保护作用。方法:本组22例晚期肺癌和晚期乳腺癌患者均接受了全身化疗,在化疗过程中均出现了2～4级神经毒性(NCI毒性评分)。在随后的化疗周期中,患者继续用原化疗方案治疗,同时加用胸腺肽α1,化疗前4天每天1.6mg,化疗开始后1.6mg每周两次,共用1～3周。化疗前及化疗后每周进行神经系统毒性反应评估。结果:10例患者(45.4%)神经系统毒性作用由化疗前的2～4级降至2级以下,另12例患者神经系统症状无明显改善。结论:胸腺肽α1可能有改善化疗所致神经毒性的作用。

BACKGROUND &OBJECTIVE: Clinical trails showed that thymosin nausea,vomiting,fatigue) of chemotherapy. This study was designed to investigate the protection of thymosin METHODS: Twenty-two patients with advanced lung cancer,or advanced breast c ancer were treated with vinorelbine (25 mg/m2,d1,d8) combined with cisplatin (8 0 mg/m2,d1),or gemcitabine (1.25 g/m2,d1,d8) combined with cisplatin (80 mg/m2,d 1),or paclitaxel (80 mg/m2,d1,d8,d15) combined with carboplatin (AUC=6 d1),or pa clitaxel (80 mg/m2,d1,d8,d15) combined with epirubicin (80 mg/m2,d1). They all e xperienced grade 2 to 4 of neurotoxicities according to common toxicity criteria of National Cancer Institute after chemotherapy. The same chemotherapy regimens were combined with thymosin 6 mg twice weekly for 1-3 weeks after chemotherapy began)in the next cycle. Clin ical neurologic evaluation was performed at baseline every week. RESULTS: In 10 patients (45.4%),neurotoxicities reduced from grade 2-4 before chemotherapy to less than grade 2 after chemotherapy. CONCLUSION: Thymosin -induced neurotoxicities.